The New Hit Depression Treatment? A Ketamine-Derived Nasal Spray
After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual sales last year for its maker, Johnson and Johnson. Further Listening: -A Lawyer Says He Doesn't Need Help for Psychosis. His…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like The Journal. →
The Resurgence Of Psychedelic Psychiatry
Brief: The Promises & (Mostly) Perils of Ketamine Therapy
Ketamine: How Special is Special K?
Can Psychedelic Therapy Go Mainstream?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.